Back

Prognostic impact of LV GLS response in Fabry patients on enzyme replacement therapy

29 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Fabry disease Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Hao Chih Chang

Taipei Veterans General Hospital, Taipei (Taiwan)

7 More presentations in this session

Presentation thumbnail
Cardiovascular prognostic determinants in anderson-fabry disease: insights from a multicenter cohort study
Doctor Y. Chen (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
FollowME Fabry Pathfinders real-world registry in Spain and Portugal: cardiac and renal outcomes with migalastat in patients with Fabry disease
Professor O. Azevedo (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Apical hypertrophic cardiomyopathy: could it be Fabry?
Doctor S. Findlay (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Prevalence of pseudo-delta wave in Anderson-Fabry disease and challenges in differentiating from ventricular pre-excitation
Doctor S. Serratore (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Fabry disease screening in patients with idiopathic HCM or idiopathic LVH: preliminary data from the multicentric nationwide F-CHECK study
Doctor E. Martins (Porto, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Fabry disease

The Event

Event poster

ESC Congress 2025

29 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Evolution of cardiac damage staged with echocardiography in Fabry disease
thumbnail
Congress Presentation
Fabry cardiomyopathy: myocardial fibrosis, inflammation and reduced mannose6phosphate receptors cause low accessibility to enzyme therapy.
thumbnail
Congress Presentation
Cardiac involvement in Fabry disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources